"Ed's leadership experience will accelerate our commercial planning efforts and help Serene build a sound scientific foundation for early stage market acceptance and a worldwide launch of a non-neurotoxin alternative for relaxing facial lines."
San Ramon, California (PRWEB) September 18, 2012
Serene Medical, Inc. of San Ramon, California, is pleased to announce the appointment of Edward A. Ebbers as Vice President and Chief Commercial Officer, effective August, 2012. Mr. Ebbers has more than 25 years of medical device and pharmaceutical industry experience. He has led several successful sales and marketing teams to launch medical products worldwide.
Most recently, Mr. Ebbers was the Vice President of Marketing and Sales for Zeltiq Aesthetics, and prior to that he was the Vice President of Marketing and Sales for Thermage, the makers of ThermaCool. He has also worked for companies such as Syntex Laboratories and 3M Pharmaceuticals, and recent consulting clients MyoScience, Miramar Labs, and Genentech.
Bankim Mehta, the CEO of Serene, stated, “I am extremely pleased with the addition of Ed to our team. He has a proven track record of successful product introductions of innovative technologies, a deep knowledge of the aesthetic procedure market, and a stellar reputation in the industry. His leadership experience will accelerate our commercial planning efforts and help Serene build a sound scientific foundation for early stage market acceptance and a well-managed worldwide development and launch of a non-neurotoxin alternative for relaxing facial lines.”
About Serene Medical: The Serene minimally invasive radio-frequency device is FDA-cleared for creating a neural lesion to inhibit undesired nerve function. Early clinical trials with a prototype device have demonstrated the ability to precisely target specific nerves that control undesired muscle activity, and to produce micro-lesions on those targeted nerves to inhibit undesired muscle activity for a year or more. The company is seeking additional regulatory clearances for Europe and other markets, and will be conducting additional studies with more advanced versions of its device.